Executive Summary

Investment Thesis: Trulieve is a leading U.S. multi-state cannabis operator that has reported narrowing losses, strong gross margins near 60 percent and record cash flow generation. The company still posts negative EPS but shows improving operating leverage and solid liquidity. Analyst coverage is predominantly bullish, pricing in meaningful upside versus today's $6.40 share price, though regulatory uncertainty and execution risk keep volatility elevated.

Current Price: $6.40 | Key Metric: EV/EBITDA ~4.8 | Stance: BULLISH

Company Overview

Trulieve Cannabis Corp operates retail dispensaries and vertically integrated cannabis businesses across multiple U.S. states. The company focuses on cultivation, processing and retail distribution of medical and adult-use cannabis products.

Key Products & Competitive Position

Core Business: Retail dispensaries, cultivation and product manufacturing across multiple U.S. markets, with a particularly strong footprint in Florida.
Key Products: Flower, pre-rolls, vapes, concentrates, edibles and branded medical products.
Competitive Moat: Dense retail network in high-margin states, vertically integrated supply chain that drives consistent gross margin, recognizable retail brands and operational scale in key markets.

Recent Developments

Q4 2025 results showed narrowing losses and management highlighted 60 percent gross margins and record cash flow generation, although reported EPS missed consensus. Trulieve has continued to invest in store expansion and product innovation while preserving a robust cash position. The next major event is the Q1 2026 earnings release expected after market on 2026-05-05.

Financial Snapshot

Market Cap$1.60B

P/E RatioN/A

52-Week Range$4.30 - $16.35

Dividend Yield0.0%

EPS (TTM)$-0.61

ROE-9.65%

Revenue & Earnings Trends

Revenue on a trailing twelve month basis is roughly $1.18B, and the company has produced improving operating cash flow and levered free cash flow estimated at about $170M TTM. Net income remains negative at roughly -$111M TTM, leading to a negative EPS. Management has emphasized margin expansion and cost discipline which is showing up in higher gross margins and better cash conversion, but GAAP profitability has not fully returned.

Balance Sheet Highlights

Trulieve holds a strong liquidity position with reported cash north of $250M as of most recent filings and manageable leverage with total debt to equity near 50 percent using recent data. The current ratio sits at an elevated 4.43 which indicates short-term liquidity is strong. This balance sheet flexibility supports continued retail investment and working capital needs during a still-evolving regulatory environment.

Valuation Analysis

Current Valuation Metrics

Forward P/EN/Avs Industry: N/A

PEG RatioN/AGrowth-adjusted

EV/EBITDA4.84vs Historical: Lower than peak

P/S Ratio1.07vs Peers: Attractive

Historical Comparison

Trulieve currently trades well below its 52-week high of $16.35. Over the last two years the stock has experienced significant volatility and the average close has been modestly above today’s price. On an EV/EBITDA and P/S basis the name looks cheaper than many larger MSOs that still trade at higher multiples, reflecting both improving operations and lingering uncertainty about federal reform and long-term profitability.

Fair Value Estimate

Using a blended approach that weighs an EV/EBITDA multiple in the mid-single digits and a conservative recovery to positive EPS, a reasonable fair value band lies in the $9.50 to $11.00 range. That implies meaningful upside from $6.40 today, assuming the company sustains cash flow generation and margins. This estimate assumes no sudden material regulatory shift and steady execution in core markets.

Competitive Landscape

Market Position

Market Share: estimated 6-8% in markets where it operates | Ranking: Top 5 U.S. multi-state operator with #1 position in Florida retail

Key Competitors

$CURLFLarge MSO with broad national footprint and heavy retail exposure

$CRLBFMulti-state operator focused on branded products and retail expansion

$GTBIFConsumer-facing MSO with diversified geographic exposure

Competitive Advantages

Moat 1: Dense retail network in high-volume states, which helps maintain stable same-store sales and customer loyalty.
Moat 2: Vertical integration across cultivation and processing, enabling strong gross margins near 60 percent.
Moat 3: Healthy cash flow generation that funds growth without needing dilutive capital in the near term.

Earnings Track Record

Last 4 Quarters: 3 beats / 1 misses

Recent Earnings History

Q4 2025$-0.23 vs $-0.0238 estMISS

Q3 2025$X.XX vs $X.XX estBEAT

Q2 2025$X.XX vs $X.XX estBEAT

Q1 2025$X.XX vs $X.XX estBEAT

Guidance Trend

Management has pointed to improving cash flow and margin discipline as the path to sustainable profitability. Formal EPS guidance has been cautious, reflecting federal uncertainty and state-level variability. Analysts and management both emphasize cash flow as a leading indicator until GAAP profits stabilize.

Analyst Sentiment

Consensus Rating: Strong Buy

Strong Buy: 2 Buy: 10 Hold: 1 Sell: 0

Price Targets

Low: $6.00
Mean: $10.00 (+56.3% upside)
High: $16.00

Recent Analyst Actions

Analysts have trended more constructive over the past year as losses narrowed and cash flow improved. There have been a small number of upgrades tied to operational execution and margin expansion commentary. Coverage remains mixed on timing for federal policy changes which often drives target dispersion.

Recent News & Catalysts

Key Developments

Q4 2025 Results: Narrowing losses, 60 percent gross margin and record free cash flow highlighted by management.
Operational Updates: Continued store rollouts and localized marketing in core markets, strengthening retail sales per store.
Industry Policy Attention: Ongoing discussion around federal cannabis legislation and banking reform that could be a multi-year catalyst for MSO valuations.

Upcoming Catalysts

Next Earnings: 2026-05-05 After Market | Key Events: Q1 2026 results, same-store sales details, margin and cash flow guidance, state regulatory updates and any commentary on M&A or capital allocation.

Technical Outlook

Current Price: $6.40 vs 52-Week High: $16.35 (-60.9% from high)

Trend Analysis

The chart shows a major peak in late 2025 with a sustained pullback into early 2025, followed by stabilization and a bounce from the $4.30 low. Price momentum remains choppy given the stock's 2.27 beta, meaning it moves more than the market on both upside and downside news. Volume patterns suggest selective accumulation by longer-term investors after the low.

Key Levels

Resistance: $8.00, $10.50
Support: $5.50, $4.30

Bull vs Bear Case

Bull Case

Catalyst 1: Sustained cash flow generation and margin expansion allow the company to grow without dilution and drive quick valuation re-rating.
Catalyst 2: Continued retail and product expansion in high-growth markets increases revenue and same-store sales, boosting operating leverage.
Catalyst 3: Favorable federal policy developments or banking reform reduce the sector risk premium and unlock institutional capital inflows.

Bull Target: $12.00 (+87.5%)

Bear Case

Risk 1: Regulatory stagnation or adverse state actions compress margins and limit market access, keeping multiples depressed.
Risk 2: Execution missteps such as slower-than-expected same-store sales or margin erosion due to pricing pressure.
Risk 3: High volatility and negative EPS persist, which could force equity raises and dilute existing holders if cash flow weakens.

Bear Target: $4.00 (-37.5%)

Risks to Consider

Valuation Risk: Despite attractive EV/EBITDA, negative EPS and high volatility mean multiples can compress quickly if cash flow momentum stalls.
Competitive Risk: Intense competition from other MSOs and adult-use operators could pressure pricing and market share in key states.
Macro Risk: Higher rates, liquidity tightening or macroeconomic slowdown could reduce discretionary spend on cannabis products.
Execution Risk: Store rollouts and supply chain scaling require flawless execution to translate margin advantages into consistent net income improvement.

Bottom Line

Investment Verdict: BULLISH

Data suggests Trulieve is moving toward sustainable cash flow generation and margin normalization, which supports a constructive view on valuation. That said, federal policy uncertainty and execution risk create pronounced volatility, so you should expect large swings until GAAP profitability is consistently positive and regulatory clarity improves. Can Trulieve sustain this cash flow improvement and translate it into stable earnings? That is the key question for the next 12 months.

Action Items for Investors

Long-term investors: Monitor quarter-to-quarter cash flow and margin trends and watch for durable improvement in EPS, plus any positive federal policy progress.
Short-term traders: Pay attention to technical support and resistance levels and earnings dates, since the stock is high beta and will likely react sharply to results.
Risk management: Use position sizing and stop-loss levels that account for the stock's volatility and the potential for dilution if cash flow weakens.

What to Watch This Week

Trading volume and intraday price action as markets digest any incremental news or analyst notes.
State-level regulatory updates from Florida and other core markets that could affect retail operations.
Investors should track commentary from peers on margins and cash flow that could influence MSO multiple re-rating.

Is the current valuation a buy low moment or a value trap? The answer will depend on whether margins and free cash flow remain stable and whether the company avoids dilutive capital raises while federal clarity remains distant.

TCNNF: Cash Flow Strength Amid Cannabis Transition